Prairie Cancer Research Consortium
The overall vision of the Prairie Cancer Research Consortium (PR2C) is to create a collaborative, inclusive, equitable, and sustainable multiprovincial initiative that works towards developing new treatment strategies for patients facing cancer by enabling
precision cancer medicine research and accelerating its implementation into practice.
Officially designated as a part of the Marathon of Hope Cancer Centres Network in December 2021, the PR2C brings together researchers and clinicians at the Arnie Charbonneau Cancer Institute, the University of Calgary, the Cancer Research Institute of
Northern Alberta, the University of Alberta, Alberta Health Services (Cancer Care Alberta; Cross Cancer Institute and Tom Baker Cancer Centre), the Saskatchewan Cancer Agency, University of Saskatchewan, Cancer Care Manitoba, and the University of
Manitoba.
Goals and Objectives
Building on the unique expertise and infrastructure that already exists in the region, PR2C members will work towards three major goals:
- To accelerate the real-world application of precision oncology for cancer patients, including patients in rural and remote parts of the Prairies who may not have been eligible for clinical trials in the past;
- To strengthen the alignment between academic centres and health systems, supporting research that answers important clinical questions, now and in the future; and
- To train and educate the next generation of clinicians and scientists in precision oncology.
Partners
-
Member
-
Member
-
Member
-
Member
-
Member
-
Member
-
Member
Projects
-
Precision care and comprehensive research strategy for ovarian cancer patients: Beyond PARP inhibitors
Key ResearchersUsing molecular based tests to inform treatment for patients with advanced stage ovarian cancer following response to initial chemotherapy and/or surgery.Read more -
Characterizing genomic signatures in predicting renal cell carcinoma therapy response
Key ResearchersThe project seeks to characterize genomic backgrounds and biomarkers that could predict response or resistance to immunotherapy in patients with renal cell carcinoma.Read more -
Precision health based management of prostate cancer patients
Key ResearchersUsing advanced genomics and machine learning to better understand factors responsible for response/resistance to PARP and AKT inhibitors in prostate cancer patients to develop targeted therapies.Read more -
Precision target discovery in high-risk soft tissue sarcoma
Key ResearchersUsing genetic and molecular sequencing technologies to characterize the mutational and molecular profiles of high-risk soft-tissue sarcomas to advance precision therapies.Read more -
Searching for biomarkers associated with disease prognosis in patients with early-stage non-small cell lung cancer following surgery.Read more
-
Mapping the states of the glioblastoma cells in primary and recurrent tumours to understand how glioblastoma changes to escape current therapies and improve our ability to target relapsed tumours.Read more
-
Immunogenomics to decipher mediators of resistance to immune-mediated therapies in Multiple Myeloma
Key ResearchersDefining how the tumour microenvironment mediates response to immunotherapies in patients with multiple myeloma.Read more -
Investigating mechanisms of lymph node metastasis in oral cancer
Key ResearchersUsing genomics to understand progression and metastasis in Oral squamous cell carcinoma.Read more -
Young Women with Breast Cancer
Key ResearchersIdentifying potentially actionable targets and pathways involved in drug resistance and/or metastasis to guide treatment and inform prognosis for young females with breast cancer.Read more -
Understanding how chronic lymphocytic leukemia cells mutate in response to therapy in order to find better treatment options for patients.Read more
-
Using genomics to determine how glioblastoma cells evolve under the selective pressure of treatment with the goal of identifying new targets for intervention to help overcome therapeutic resistance.Read more
Consortium Leadership
-
Hanne
Institutional LeadMOHCCN Steering CommitteeWorking Group Chair
Ostergaard -
Roseline
Institutional Lead
Godbout -
Paula
Institutional Lead
Robson -
Deborah
Institutional Lead
Anderson -
Lynn
Institutional Lead
Dwernychuk -
Shantanu
Institutional LeadProject LeaderWorking Group Member
Banerji -
Spencer
MOHCCN Network Council
Gibson -
Jennifer
MOHCCN Steering CommitteeConsortium LeaderProject LeaderWorking Group Member
Chan
Project Management Team
-
Carolyn-Ann
Project ManagerWorking Group Member
Robinson
Project and Cohort Leaders
-
Shantanu
Institutional LeadProject LeaderWorking Group Member
Banerji -
Nizar
Project Leader
Bahlis -
Paola
Project Leader
Neri -
Sorana
Research LeadProject LeaderWorking Group Member
Morrissy -
Michael
Project Leader
Monument -
John
Project LeaderWorking Group Member
Lewis -
Tarek
Project Leader
Bismar -
Marshall
Project LeaderWorking Group Member
Pitz -
Jennifer
MOHCCN Steering CommitteeConsortium LeaderProject LeaderWorking Group Member
Chan -
Laura
ResearcherProject Leader
Hopkins -
Daniel
ResearcherProject Leader
Heng -
Ana
ResearcherMOHCCN Clinician-Scientist Award Winner
Nikolic -
Pinaki
ResearcherProject Leader
Bose -
Martin
ResearcherProject Leader
Hyrcza -
Carrie
ResearcherProject Leader
Shemanko -
Afshin
ResearcherProject Leader
Raouf -
Versha
ResearcherProject Leader
Banerji -
Sachin
MOHCCN Steering CommitteeInstitutional LeadProject LeaderResearcher
Katyal
Related News
-
Celebrating exciting milestones for our Network!
"We now have over 3,000 full genomes profiled as part of this initiative, nearly 700 of which already have their corresponding clinical data." -
MOHCCN Update: Our Network is growing!
Dr. André Veillette, Executive Director of the MOHCCN, presents the latest updates on our growing Network! -
MOHCCN Pathfinder Project clears the way for future data sharing between Network members
Through its Pathfinder Project, the MOHCCN has developed and deployed a technical tool that allows members to upload, discover – and eventually access – the data needed to accelerate precision medicin... -
Four outstanding clinician-scientists named inaugural Clinician-Scientist Awardees following Marathon of Hope Cancer Centres Network competition
Four early-career clinician-scientists in Alberta, Ontario and Quebec are the first recipients of the inaugural Clinician-Scientist Award funded by the Marathon of Hope Cancer Centres Network (MOHCCN)...